Trials / Completed
CompletedNCT03478020
Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study
Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125 in healthy female subjects on combination oral contraceptives (COC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AQX-1125 | Investigational Drug |
| DRUG | Combined Oral Contraceptive | COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE) |
Timeline
- Start date
- 2017-11-22
- Primary completion
- 2018-03-29
- Completion
- 2018-04-05
- First posted
- 2018-03-27
- Last updated
- 2018-06-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03478020. Inclusion in this directory is not an endorsement.